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Evidence on relative treatment effects concerning OS, progression-free survival 
(PFS) and discontinuation due to any reason (treatment persistence) and adverse 
events (tolerability) was estimated using a mixed treatment comparison following a 
systematic review of randomized clinical trials enrolling post-menopausal women 
with hormone-sensitive ABC. Health service costs were included and a lifetime 
perspective adopted (5% annual discount rate). Results: Everolimus+exemestane 
is estimated to significantly delay progression or death (HR PFS = 0.53; 95% CI: [0.37; 
0.76]) and to increment life expectancy by 6.8 months in comparison to fulvestrant 
(HR OS = 0.82; 95% CI: [0.50; 1.36]), resulting in a 0.45 discounted life year (LY) gain. 
Corresponding incremental health service costs amount to 16,544€ /patient starting 
everolimus+exemestane. This results in an incremental cost-effectiveness ratio 
of 36,703€ /LY gained with everolimus+exemestane. Probabilistic sensitivity analy-
sis showed a greater than 60% probability of everolimus+exemestane being cost-
effective against fulvestrant, at a willingness to pay of 50,000€ /LY. ConClusions: 
We evidence how valuable information from clinical trials can be pooled and used 
to inform about the therapeutic and economic value of guideline recommended 
therapies for advanced breast cancer.
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objeCtives: To assess the cost-effectiveness of pembrolizumab to treat unre-
sectable or metastatic melanoma in patients progressing after treatment with 
ipilimumab, and if BRAFv600positive mutation, a BRAF inhibitor. The relevant com-
parator is English best supportive care (BSC), including dacarbazine. Methods: 
A three-state partitioned survival model was developed to estimate the cost-
effectiveness of pembrolizumab compared with BSC over a 30 year time horizon. 
Efficacy and quality of life were derived from KEYNOTE-002, a phase II clinical 
trial comparing pembrolizumab to investigators choice of chemotherapy. Since 
overall survival (OS) data were affected by a high degree of crossover, various 
statistical models were used to adjust for crossover with the 2-stage adjust-
ment, using progression as a secondary baseline, found to be the most appro-
priate. Pembrolizumab OS was extrapolated using long-term ipilimumab data, 
supported by results of the KEYNOTE-002 clinical trial, and melanoma clinical 
experts’ feedback on commonality of expected long-term survival profile. Quality 
of life was based on time to death health states using KEYNOTE-002 EQ-5D data. 
Adverse events were incorporated based upon KEYNOTE-002 data which showed 
a favourable safety profile when compared to chemotherapy, with grade 3-5 
adverse events numerically higher in the chemotherapy control arm. Results: 
Pembrolizumab was predicted to increase the life expectancy of patients by 
1.59 years, which corresponds to a gain of 1.19 QALYS. In the base case analy-
sis, the ICER is £42,923 (confidential discount included). These results are sensi-
tive to curve fit parameters for progression-free survival and the hazard-ratio 
for overall survival estimated from the cross-over adjustment and a robust to 
changes in value parameters and assumptions in the cost-effectiveness analy-
sis. ConClusions: As an end of life therapy for English patients with advanced 
melanoma previously treated with ipilimumab, pembrolizumab is a cost-effective 
therapeutic option when compared to best supportive care (including conventional 
chemotherapy).
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objeCtives: Breast cancer screening is established practice in most developed 
countries, typically with a two-year screening interval. The cost-effectiveness evi-
dence supporting screening is primarily from simulation models. It is recognised 
that cost-effectiveness analyses (CEAs) of biennial screening should include trien-
nial strategies as comparators if the incremental cost-effectiveness ratio (ICER) is to 
be correctly estimated. The objective of this study is to assess how many published 
CEAs of breast screening include triennial comparator strategies against which to 
compare biennial screening. Methods: We assessed 26 simulation-based CEAs 
of breast screening of average-risk women identified in a recently published sys-
tematic review. We reviewed how many included triennial comparators to biennial 
screening and assessed the relevant ICERs. Results: Of the 26 CEAs, 18 did not 
include comparators with intervals of three years or more. Therefore the ICER esti-
mates for biennial screening from these studies are on the basis of insufficient com-
parators. Of the remaining studies, six included the necessary triennial comparators. 
Of these, two provide ICERs of biennial screening that are clearly acceptable relative 
to commonly cited willingness to pay thresholds. The results from the remaining 
four studies leave it unclear if biennial screening is cost-effective. ConClusions: 
Despite the widely expressed view that breast screening is cost-effective, the pro-
portion of published CEAs that provide appropriately estimated ICERs of biennial 
screening is small and the number clearly indicating biennial screening is cost-
effective is even smaller. This does not suggest that biennal breast screening is cost-
ineffective, but rather that most CEAs published to date do not present sufficient 
evidence to demonstrate cost-effectiveness.
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objeCtives: Mantle cell lymphoma (MCL) is a rare but aggressive form of non-Hodg-
kin’s lymphoma with one of the poorest outlooks. In Scotland, patients unsuitable 
for stem cell transplantation (SCT) primarily receive rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisone (R-CHOP). The LYM-3002 trial demonstrated 
that the use of bortezomib, rituximab, cyclophosphamide, doxorubicin and pred-
nisone (VR-CAP) almost doubled progression-free survival (PFS) relative to R-CHOP 
(24.7 vs 14.4 months; HR= 0.63, p< 0.001). The objective of this analysis was to assess 
the cost effectiveness of VR-CAP versus R-CHOP as first-line treatment for MCL-
patients unsuitable for SCT, from the perspective of the Scottish National Health 
Service (NHS). Methods: A cost-effectiveness model was constructed based upon 
line of treatment, progression status and survival; extrapolating LYM-3002 clinical 
trial data using parametric models fit to PFS, overall survival (OS) and treatment-
free interval Kaplan–Meier curves. Utilities were derived from trial-based EQ-5D 
data, supplemented with published values for long-term health status. Resource 
use including second-line treatment was taken from the LYM-3002 trial and UK 
clinician advice. Costs were derived from standard UK sources. Probabilistic and 
structural sensitivity analyses were conducted to assess the uncertainty of the 
results. Results: Total lifetime costs were £45,453 and £26,291 for VR-CAP vs. 
R-CHOP. Treatment with VR-CAP resulted in greater life years (7.49) compared to 
R-CHOP (6.58), and quality-adjusted life years (QALYs), 4.05 and 3.31 for VR-CAP and 
R-CHOP, respectively. Thus the additional cost associated with VR-CAP was partially 
offset by additional benefit; resulting in an incremental cost-effectiveness ratio of 
£23,020. Probabilistic sensitivity analysis estimated an 82% chance that VR-CAP 
was cost effective below £30,000/QALY. The model was most sensitive to extrapola-
tion assumptions for PFS and OS and utility associated with post-progression from 
second-line treatment. ConClusions: VR-CAP is a cost-effective treatment for 
previously untreated patients with MCL who are unsuitable for SCT in NHS Scotland.
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objeCtives: Genetically-targeted therapies are both promising and costly advances 
in the field of oncology. This study aims to evaluate the cost-effectiveness of vemu-
rafenib versus ipilimumab as first-line treatments in patients with BRAF V600 
mutation-positive unresectable or metastatic melanoma from a Spanish health-
care system perspective. Methods: We performed a cost-effectiveness analysis to 
compare both strategies for patients with BRAF positive metastatic melanoma using 
a probabilistic model. Since head-to-head trials are not available, overall (complete 
and partial) response rates were obtained from the phase III randomized-controlled 
trials of vemurafenib (57.0%; 95% CI 51.6-65.2%) and ipilimumab (15.2%; 95% CI 12.2-
18.2%). The cost of treatment regimens was calculated using the recommended dose 
schedules as per the Summary of Product Characteristics. The treatment duration 
with vemurafenib was 6.9 months (median progression-free survival). Four doses 
of ipilimumab were considered. The prices used in the analysis correspond to those 
currently approved in Spain (in EUR, 2015).Monte-Carlo simulation was chosen as 
it allows simulating the effect of changes in different parameters obtained from 
clinical studies and other sources to describe real-life distributions. Parameters 
used in the simulation were the progression free survival, body weight and overall 
response rates. Additional threshold sensitivity analyses for possible ipilimumab 
price discounts were performed. Results: 1,000 model iterations were generated. 
The cost per overall response with vemurafenib and ipilimumab was € 111,928 
(95% CI € 108,403; € 115,969) and € 447,462 (95% CI € 370,285; € 538,214) respectively. 
Therefore, the cost of ipilimumab per patient that responds to treatment would be 
4.0 (3.4-4.6) times greater than treating with vemurafenib. The cost per responder 
would be equal amongst both treatments, only with a discount of 71.1% in the price 
of ipilimumab. ConClusions: In BRAF V600 mutation-positive unresectable or 
metastatic melanoma, first-line vemurafenib could reduce the health care costs 
per overall response in comparison to ipilimumab.
PCN133
thEraPEutiC aNd ECoNomiC valuE of EvErolimus Plus ExEmEstaNE for 
thE trEatmENt of PostmENoPausal womEN with hormoNE rECEPtor-
PositivE, hEr2/NEu NEgativE advaNCEd brEast CaNCEr
Félix J, Almeida J, Ferreira D, Rabiais S, Vandewalle B
Exigo Consultores, Alhos Vedros, Portugal
objeCtives: Up to 70% of women with hormone-sensitive advanced breast cancer 
(ABC) need further therapy lines following first-line hormonal therapy. Although 
treatment guidelines provide useful recommendations for treating patients with 
ABC they rarely compare different treatment options or provide guidance on how to 
optimize their value. This research aimed to assess the therapeutic and economic 
value of everolimus 10mg plus exemestane 25mg daily (everolimus+exemestane) in 
comparison to fulvestrant (500mg intramuscularly on days 0, 14 and 28, and every 28 
days thereafter) for the treatment of hormone receptor-positive, HER2/neu negative 
ABC postmenopausal women who failed first-line hormonal therapy. Methods: 
We used a discrete-time, state-transition model to estimate the long term overall 
survival (OS) and treatment costs in ABC patients failing first-line hormonal therapy. 
